More Studies For Bridion (sugammadex)?

Discussion in 'Organon' started by Anonymous, Mar 7, 2008 at 7:22 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    wake up, OBS managmenet had equal expertise in anesthesia.....do we need to say more?
     

  2. Anonymous

    Anonymous Guest

    Man are you guys completely fucked. You have no generic strategy for Zemuron, delay after delay for products you try to launch, LM running Suggamdex and SP believing the product is worth tons of money. No wonder you stock remains below $20. Can you say,"take over"!!! We are coming for you soon. I would say bend over and enjoy it, but you are pretty used to that from Fred and Carrie these days. We will at least kiss you )(.
     
  3. Anonymous

    Anonymous Guest

    The above poster gets it. OBS is gone and SP is here. Sales hasn’t seen anything yet, you have be listening to the lullaby music in the background while SP has ripped the best from OBS, kept the Kool-Aid drinkers (while demoting them), and now your sales managers and you are next. Wake up the changes are coming and yes sugammadex will be priced in the hundreds per dose…. Did you here that…..
     
  4. Anonymous

    Anonymous Guest

    we used to have the a team taht new what to do. The sleas team talked regularly tothe marketers who talked to the martket researches who talked to Sales Ops who talked to meeintg planning to interafcted with training. Now that is gonoe. No more talking. Sugammadex be nothing without anesthesia "know how." That knoweldge is long gone. Only thing left is same RDs, DMs and reps. and well Janet Chow
     
  5. Anonymous

    Anonymous Guest

    you either need a new keyboard or some typing lessons, or both.....
    There was nothing like a lot of anesthesia knowledge before S-P, but I am sad to say that a lot of what little we had is gone.....
     
  6. Anonymous

    Anonymous Guest

    Sugammadex has been provisionaly approved in Europe (do any of you know where that is!!??)

    Main issues are - a total lack of understanding of the market from SP. Anyone worth their salary has left Organon, and SP management are seen as a bunch of jokers by the company, and more importantly by the key leaders in anaesthesia.

    Secondly, they will price it out of the market, or at best it will only be used in emergency situations.

    Anyone left in anaesthesia, get out while you can!
     
  7. Anonymous

    Anonymous Guest

    people in the clinic will need to have five signatures on a request in triplicate before they may use the stuff at the price level that is being rumoured.... (which also might be some stage setting trick)

    anyway, the original organon 'team' had the same understanding of the field of anesthesia as the current team ...... the lack of willingness to listen to those who could know never kept them from dreaming up crazy strategies and the same holds true now.

    The drug will sell itself, the price will probably rapidly adjust itself and fred gets to explain disappointing sales.....
     
  8. Anonymous

    Anonymous Guest

    What do you think the price will be set at?
     
  9. Anonymous

    Anonymous Guest

    don't know, only that it will be too high for the anesthesia arena not to hurt, not just slightly high but probably way over the top........
     
  10. Anonymous

    Anonymous Guest

    It doesn't matter what the price will be because it won't be SP who ultimately will sell this POS. Let's hope the new company that buys SP will be smart and finally do away with Liana M and anyone associated with her.

    I don't believe I've ever met a bigger piece of crap. I'm 100% sure that this launch will go down the crapper along with SP.

    Can you say, "divest"?
     
  11. Anonymous

    Anonymous Guest

    Bridion will be the trade name ex-US. US trade name TBD.
     
  12. Anonymous

    Anonymous Guest

    us trade name was already agreed upon with FDA
    could be this one:

    www.wipo.int:
    (954428) ESVERA.
    (151) Date of the registration
    11.02.2008
    (111) Number
    11.02.2008
    (180) Expected expiration date of the registration/renewal
    11.02.2018
    (171) Expected duration of the registration
    10
    (732) Name and address of the holder of the registration
    N.V. Organon
    Kloosterstraat 6
    NL-5349 AB Oss (NL)
    (812) Contracting State or Contracting Organization in the territory of which the holder has a real and effective industrial or commercial establishment
    BX
    (740) Name and address of the representative
    N.V. Organon
    Kloosterstraat 6
    NL-5349 AB Oss (NL)
     
  13. Anonymous

    Anonymous Guest

    The price will be $400+
     
  14. Anonymous

    Anonymous Guest

    It will be Ezvera, not Esvera. Price will be no where near $400.
     
  15. Anonymous

    Anonymous Guest

    Bridion got approval from EMEA :)
     
  16. Anonymous

    Anonymous Guest

    Non Approved USA. Last one out turn out the lights, good night, good bye.
     
  17. Anonymous

    Anonymous Guest

    When will be the soonest possible time the FDA could/would approve?
     
  18. Anonymous

    Anonymous Guest

    you'd better off predicting the winning lottery numbers than what FDA will do and when....
    Personally I think the non-approvable letter reeks of politics rather than true pharmacovigilance by FDA.
     
  19. Anonymous

    Anonymous Guest

    I think the FDA looked at Liana and run...NAsty
     
  20. Anonymous

    Anonymous Guest

    You mean to tell me that her tight mini-skirt was a turn off? How can that be? She is hot...if you don't believe me just ask her!